Abstract 152P
Background
The Belgian Precision initiative aims to maximize the implementation of tumor-agnostic NGS in patients with advanced cancer and enhance access to molecularly-guided treatment options (MGTOs). Academic tumor-agnostic basket phase 2 studies are part of this initiative. The current investigator-driven trial aimed to investigate olaparib efficacy in advanced cancers with a pathogenic or likely pathogenic mutation (germline or somatic) in a gene that plays a role in homologous recombination (HR).
Methods
Open-label multi-cohort phase 2 study that examines the efficacy of olaparib in patients with an HR gene mutation in their tumor and failed SoC. Patients with a somatic or germline mutation in the same gene define a cohort. For each cohort, a Simon minimax two-stage design was used. If a response was observed in the first 13 patients, 14 additional patients were included (type I error rate of 5% and a power of 80% when the true response rate is 20%). Here, we report the results on four completed cohorts: patients with a BRCA1, BRCA2, CHEK2 or ATM mutation.
Results
The overall objective response rate across different tumor types was 11% in the BRCA1 (N=27) and 21% in the BRCA2 (N=27) mutated cohorts. Partial responses were seen in pancreatic cancer, gallbladder cancer, endocrine carcinoma of the pancreas and parathyroid cancer. One patient with a BRCA2 germline mutated colon cancer has an ongoing CR with 19+ months on treatment. mPFS in responding patients is 14+ months (5-34+ months). The clinical benefit rate was 63% in the BRCA1 and 46% in the BRCA2 mutated cohorts. No clinical activity was observed in the ATM (N=13) and CHEK2 (N=14) cohorts. Safety data were consistent with the known profile of olaparib.
Conclusions
Olaparib showed efficacy in different cancer types harboring somatic or germline mutations in the BRCA1/2 genes but not in ATM and CHEK2. Patients with any cancer type harboring BRCA1/2 mutations should have access to olaparib with real-world documentation of efficacy in a retrospective register.
Clinical trial identification
NCT03967938.
Editorial acknowledgement
Legal entity responsible for the study
Belgian Society of Medical Oncology (BSMO).
Funding
Kom op tegen Kanker , Fondation contre le Cancer, AstraZeneca and MSD (unrestricted grant, olaparib).
Disclosure
S.R. Joris: Non-Financial Interests, Institutional, Advisory Role: AstraZeneca; Non-Financial Interests, Institutional, Sponsor/Funding: AstraZeneca, MSD. H. Denys: Non-Financial Interests, Institutional, Advisory Role: pfizer, Roche, PharmaMar, AstraZeneca, Eli Lilly, Novartis, Amgen, GSK, Seagen, MSD, Gilead. P.G. Aftimos: Non-Financial Interests, Institutional, Research Grant: Roche; Non-Financial Interests, Institutional, Other, Consulting: Boehringer Ingelheim, Macrogenics, Roche, Novartis, Amcure; Financial Interests, Institutional, Other, Consulting: Servier, G1 therapeutics, Radius, Deloitte; Financial Interests, Institutional, Other, Honoraria: Synthon, Amgen, Novartis; Financial Interests, Institutional, Other, Honoraria: Gilead, Lilly, Daiichi Sankyo. All other authors have declared no conflicts of interest.
Resources from the same session
227P - Biomarkers for novel NK checkpoint inhibitor anti LLT1 antibody, ZM008: Patient transcriptome analysis
Presenter: M. S. Madhusudhan
Session: Poster session 01
228P - Biomarker discovery via meta-analysis of immunotherapy clinical trials in cancer
Presenter: Benjamin Haibe-Kains
Session: Poster session 01
230P - Fibroblast growth factor receptor (FGFR) co-alteration (co-alt) landscape and its impact on erdafitinib (erda) response in the phase II open-label, single-arm RAGNAR trial
Presenter: Yohann Loriot
Session: Poster session 01
231P - Time to deterioration of quality of life as a surrogate of OS: A trial-level surrogacy analysis
Presenter: Adel Shahnam
Session: Poster session 01
232P - Identification of ‘secondary’ germline cancer predisposition variants from somatic tumour testing: Should we evolve towards universal screening?
Presenter: Alejandro Gallego Martinez
Session: Poster session 01